Contact Us for a Free Consultation 415-761-8761

Blog

Investigation of Acer Therapeutics

Posted by M. Ryder Thomas | Jul 29, 2020 | 0 Comments

Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss

Acer misrepresented that a conversation it had with the U.S. Food and Drug Administration regarding its drug candidate EDVISO.  Acer claimed publicly that “the FDA agreed that additional clinical development is not needed” for the drug.  Acer went on to raise almost $59 million in two offerings based on this information.  However, contrary to Acer's public comments, the FDA had not approved the new drug application for EDVISO.  In June 2019, when Acer revealed that the FDA needed it to “conduct an adequate and well-controlled trial” to determine EDVISO's effects in patients, Acer's stock price fell $15.16 per share, or over 75%, to close at $4.12 per share. On June 16, 2020, U.S. District Court Judge Gregory H. Woods denied in part Acer's motion to dismiss plaintiffs' claims, stating that plaintiffs had plausibly alleged securities fraud claims. On July 21, 202, Judge Woods subsequently denied Defendants' motion to reconsider his decision, paving the way for litigation to proceed.

About the Author

M. Ryder Thomas

PRACTICE AREAS Antitrust, Securities Litigation, Consumer Protection, Complex Business and Financial Litigation; Class Action Litigation EXPERIENCE Ryder is an experienced litigator with particular expertise in the areas of complex business litigation as well as antitrust, securities fraud, an...

Comments

There are no comments for this post. Be the first and Add your Comment below.

Leave a Comment

Contact Us Today!

Brownstein Law Group is committed to answering your questions.

We’ll gladly discuss your case with you at your convenience. Contact us today to schedule an appointment.

Menu